Skip to main content
SpringerLink
Log in

7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine

  • Original Articles
  • Tumor Metastasis, Immunomodulator, Tumor Vaccine Adjuvant, NK Cells
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

We have shown previously that loxoribine exhibits adjuvant activity for B cells, activates natural killer (NK) cells, and enhances the activation of lymphokine-activated killer cells by interleukin-2 (IL-2). In this study, we examined loxoribine for protective effects in a B16 melanoma lung tumor metastasis model. Significant inhibition of B16 metastasis was seen in mice given a single injection of 2 mg loxoribine as late as day 3 of tumor growth but the greatest inhibition (96%) was seen in mice given four injections of loxoribine on alternate days starting the day before tumor injection. In experiments in which both IL-2 and loxoribine were administered, both agents were active when tested alone, but the combination of IL-2 and loxoribine gave significantly greater inhibition of metastasis. Loxoribine partially inhibited the development of tumors in mice that had been depleted of NK cells by the administration of anti-asialo-GM1 or anti-NK1. 1 antibodies and in NK-deficient beige mice. In all cases, protection was seen only when smaller tumor inocula were injected. Taken together, these data suggest that both NK and non-NK cell populations or effector mechanisms with antitumor activity were activated by loxoribine. Since substituted guanosine analogs have been shown to have adjuvant activity in B cell systems, we evaluated whether loxoribine was active as an adjuvant in a tumor protection model. Mice immunized with both irradiated tumor cells and loxoribine developed a significantly lower number of lung tumors when challenged by live B16 tumor cells, whereas mice injected with either vaccine or loxoribine alone were not protected. There was a clear dose response seen with both loxoribine and the vaccine preparations. These data suggest that loxoribine may be useful in tumor therapy as an immunomodulator or as an adjuvant for use with tumor vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Whiteside TL, Herberman RB (1989) The role of natural killer cells in human disease. Clin Immunol Immunopathol 53: 1

    PubMed  Google Scholar 

  2. Schantz SP, Brown BW, Lira E, Taylor DL, Beddingfield N (1987) Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer. Cancer Immunol Immunother 25: 141

    PubMed  Google Scholar 

  3. Haller O, Hansson M, Kiessling R, Wigzell H (1977) Role of non-conventional killer cells in resistance against syngeneic tumor cells in vivo. Nature 270: 609

    PubMed  Google Scholar 

  4. Riccardi C, Santoni A, Barlozzari T, Pucetti P, Herberman RB (1980) In vivo natural reactivity of mice against tumor cells. Int J Cancer 25: 475

    PubMed  Google Scholar 

  5. Hanna N, Burton RC (1981) Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. J Immunol 127(5): 1754

    PubMed  Google Scholar 

  6. Pollack SB, Hallenbeck LA (1982) In vivo reduction of NK activity with anti-NK1 serum: direct evaluation of NK cells in tumor clearance. Int J Cancer 29: 203

    PubMed  Google Scholar 

  7. Pollack SB (1983) In vivo functions of natural killer cells. Surv Synth Pathol Res 2: 93

    Google Scholar 

  8. Barlozzari T, Leonhardt J, Wiltrout RH, Herberman RB, Reynolds CW (1985) Direct evidence for the role of LGL in the inhibition of experimental tumor metastase. J Immunol 134: 2783

    PubMed  Google Scholar 

  9. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823

    PubMed  Google Scholar 

  10. Mazumder A, Rosenberg SA (1984) Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 159: 495

    PubMed  Google Scholar 

  11. Andreesen R, Scheibenbogen C, Brugger W, Krause S, Meerpohl H-G, Leser H-G, Engler H, Lohr GW (1990) Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating monocytes: a new approach to cancer immunotherapy. Cancer Res 50: 7450

    PubMed  Google Scholar 

  12. Soldateschi D, Censini S, DeGori V, Antoni G, Tagliabue A, Boraschi D (1984) Macrophage antitumor activity in vitro. Comparative analysis of cytolytic, cytostatic, and cytotoxic activities of mouse macrophages and human monocytes. Immunobiol 166: 251

    Google Scholar 

  13. Fidler IJ, Darnell JH, Budman MB (1976) Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanvalin A. Cancer Res 36: 3608

    PubMed  Google Scholar 

  14. Alexander RB, Rosenberg SA (1991) Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes. J Immunother 10: 389

    PubMed  Google Scholar 

  15. Whiteside TL (1991) Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations. In vivo 5: 553

    PubMed  Google Scholar 

  16. Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, Birch R, Yannelli JR, Maleckar JR, Sterruzza A, Arnold J, West WH (1991) Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. Cancer 68: 1

    PubMed  Google Scholar 

  17. Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA (1988) Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Res 48: 7140

    PubMed  Google Scholar 

  18. Eisenthal A, Cameron RB, Rosenberg SA (1990) Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-α and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. J Immunol 144: 4463

    PubMed  Google Scholar 

  19. Eisenthal A, Rosenberg S (1989) Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin-2. Cancer Res 49: 6953

    PubMed  Google Scholar 

  20. Ojo E (1979) Positive correlation between the levels of natural killer cells and the in vivo resistance to syngeneic tumor transplants as influenced by various routes of administration ofCorynebacterium parvum bacteria. Cell Immunol 45: 182

    PubMed  Google Scholar 

  21. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161: 1169

    PubMed  Google Scholar 

  22. Shimoda K, Saito T, Kobayashi M, Nomoto K (1992) Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432. Biotherapy 5: 63

    PubMed  Google Scholar 

  23. Yang SC, Fry KD, Grimm EA, Roth JA (1990) Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor α. Arch Surg 125: 220

    PubMed  Google Scholar 

  24. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surgery 210: 474

    Google Scholar 

  25. Ettinghausen SE, Rosenberg SA (1986) The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Springer Semin Immunophathol 9: 51

    Google Scholar 

  26. Rosenberg SA (1988) The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surgery 208: 121

    Google Scholar 

  27. Rodolfo M, Salvi C, Bassi C, Parmiani G (1990) Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model. Cancer Immunol Immunother 31: 28

    PubMed  Google Scholar 

  28. Rosenberg SA, Lotze MT, Mule JJ (1988) NIH Conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Int Med 108: 853

    Google Scholar 

  29. Rosenberg SA, Schwarz SL, Spiess PJ (1988) Combination immunotherapy for cancer. Synergistic antitumor interactions of interleukin-2, alpha interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 80: 1393

    PubMed  Google Scholar 

  30. Cole III JS, Gruber J (1992) Progress and prospects for human cancer vaccines. J Natl Cancer Inst 84: 18

    PubMed  Google Scholar 

  31. Stevenson FK (1991) Tumor vaccines. FASEB J 5: 2250

    PubMed  Google Scholar 

  32. Hoover HC Jr, Surdyke MG, Dangel RB, Peters LC, Hanna MG Jr (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55: 1236

    PubMed  Google Scholar 

  33. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ (1990) Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunological results in 64 patients. J Clin Oncol 8: 1858

    PubMed  Google Scholar 

  34. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E-I, Taniyama T, Sakata T (1989) Exogenous expression of mouse interferon γcDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 86: 9456

    PubMed  Google Scholar 

  35. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217

    PubMed  Google Scholar 

  36. Asher AL, Mule JJ, Kasid A, Restifo NP, Salo JC, Reichert CM, Jaffe G, Fendly B, Kreigler M, Rosenberg SA (1991) Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 146: 3227

    PubMed  Google Scholar 

  37. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397

    PubMed  Google Scholar 

  38. Naito H, Ziegler MM, Miyakawa A, Tokunaga O, Sasaki M (1992) Establishment of animal liver metastatic model for C-1300 murine neuroblastoma and immunotherapy for it using OK-432, streptococcus preparation. J Surg Res 52: 79

    PubMed  Google Scholar 

  39. Bukowski JF, Biron CA, Welsh RM (1983) Elevated natural killer cell-mediated cytotoxicity, plasma interferon, and tumor cell rejection in mice persistently infected with lymphocytic choriomeningitis virus. J Immunol 131: 991

    PubMed  Google Scholar 

  40. Minato N, Bloom BR, Jones C, Holland J, Reid LM (1979) Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice. J Exp Med 149: 1117

    PubMed  Google Scholar 

  41. Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI (1989) Induction of human lymphokine-activated killer cells by IFN-α and IFN-γ. J Immunol 143: 4282

    PubMed  Google Scholar 

  42. McCune CS, Marquis DM (1990) Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 50: 1212

    PubMed  Google Scholar 

  43. Crump WL 3rd, Owen-Schaub LB, Grimm EA (1989) Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Res 49: 149

    PubMed  Google Scholar 

  44. Chouaib S, Bertoglio J, Blay JY, Marchiol-Fournigault C (1988) Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2. Proc Natl Acad Sci USA 85: 6875

    PubMed  Google Scholar 

  45. Richard KA, Mortensen RF, Tracey DE (1987) Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo. J Biol Response Mod 6: 647

    PubMed  Google Scholar 

  46. Eggermont AMM, Sugarbaker PH, Marquet RL, Jeekel J (1988) In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models. Cancer Immunol Immunother 26: 23

    PubMed  Google Scholar 

  47. Sharma BS, Balazs L, Jin A, Jolley WB, Robins RK (1991) Successful immunotherapy of murine melanoma metastases with 7-thia-8-oxoguanosine. Clin Exp Metastasis 9: 429

    PubMed  Google Scholar 

  48. Sharma BS, Balazs L, Jin A, Wang JC, Jolley WB, Robins RK (1991) Potentiation of the efficiacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine. Cancer Immunol Immunother 33: 109

    PubMed  Google Scholar 

  49. Goodman MG, Weigle WO (1983) Manifold amplification of in vivo immunity in normal and immunodeficient mice by ribonucleosides derivatized at C8 of guanine. Proc Natl Acad Sci USA 80: 3452

    PubMed  Google Scholar 

  50. Pope BL, Chourmouzis E, Sigindere J, Capetola RJ, Lau CY (1992) In vivo enhancement of murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine). Int J Immunopharmacol 14: 1375

    PubMed  Google Scholar 

  51. Pope BL, Chourmouzis E, Sigindere J, MacIntyre PJ, Capetola RJ, Lau CY (1993) In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine). Cell Immunol 147: 302

    PubMed  Google Scholar 

  52. Koo GC, Peppard JR (1984) Establishment of monoclonal anti-NK-1.1 antibody. Hybridoma 3: 301

    PubMed  Google Scholar 

  53. Cohen SA, Tzung SP, Doerr RJ, Goldrosen MH (1990) Role of asialo-GM1 positive liver cells from athymic nude or polyinosinic-polycytidilic acid treated mice in supressing colon-derived experimental hepatic metastasis. Cancer Res 50: 1834

    PubMed  Google Scholar 

  54. Seaman WE, Sleisenger M, Eriksson E, Koo GC (1987) Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immuity. J Immunol 138: 4539

    PubMed  Google Scholar 

  55. Pollack SB (1982) Direct evidence for anti-tumor activity by NK cells in vivo: growth of B16 melanoma in anti-NK1.1 treated mice. In: NK cells and other natural effector cells. Academic Press, p 1347

  56. Karre K, Klein GO, Kiessling R, Klein G, Roder JC (1980) In vitro NK-activity and in vivo resistance to leukemia: studies of beige, beige/nude and wild type hosts on C57BL background. Int J Cancer 26: 789

    PubMed  Google Scholar 

  57. Talmadge JE, Meyers KM, Prieur DJ, Starkey JR (1980) Role of NK cells in tumour growth and metastasis in beige mice. Nature 284: 622

    PubMed  Google Scholar 

  58. Jin A, Mhaskar S, Jolley WB, Robins RK, Ojo-Amaize EA (1990) A novel guanosine analog, 7-thia-8-oxoguanosine, enhances macrophage and lymphocyte antibody-dependent cell-mediated cytotoxicity. Cell Immunol 126: 414

    PubMed  Google Scholar 

  59. Koo GC, Jewell ME, Manyak CL, Sigal NH, Wicker LS (1988) Activation of murine natural killer cells and macrophages by 8-bromoguanosine. J Immunol 140: 3249

    PubMed  Google Scholar 

  60. Smee DF, Alaghamandan HA, Cottam HB, Sharma BS, Jolley WB, Robins RK (1989) Broad spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine a novel immunopotentiating agent. Antimicrob Agents Chemother 33: 1487

    PubMed  Google Scholar 

  61. Smee DF, Alaghamandan HA, Jin A, Sharma BS, Jolley WB (1990) Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice. Antiviral Res 13: 91

    PubMed  Google Scholar 

  62. Pope BL, Choumouzis E, Victorino L, MacIntyre JP, Capetola RJ, Lau CY (1993) Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2. J Immunol 151: 3007

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. R. W. Johnson Pharmaceutical Research Institute, 19 Green Belt Drive, M3C IL9, Don Mills, Ontario, Canada

    Barbara L. Pope, JoAnn Sigindere, Erika Chourmouzis & Philip MacIntyre

  2. Department of Immunology, Research Institute of Scripps Clinic, 10666 North Torrey Pines Road, 92037, La Jolla, California, USA

    Michael G. Goodman

Authors
  1. Barbara L. Pope
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. JoAnn Sigindere
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erika Chourmouzis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Philip MacIntyre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael G. Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pope, B.L., Sigindere, J., Chourmouzis, E. et al. 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine. Cancer Immunol Immunother 38, 83–91 (1994). https://doi.org/10.1007/BF01526202

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01526202

Key words

Search

Navigation